Accounts payable and accrued expenses Accounts Receivable, Net, Current Accounts receivable Debt issuance cost, accumulated amortization Additional paid-in-capital Additional Paid-In Capital Adjustments to reconcile net loss to net cash used in operating activities Amendment Flag Total assets Total assets Assets Total current assets Total current assets Current assets ACQUISITION OF BIO-QUANT Capital lease payable - current portion Capital lease payable Cash and cash equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Sales of investment in consolidated subsidiary: Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Common Stock disclosure COMMON STOCK TRANSACTIONS Common Stock Common stock, par value Common stock, shares authorized Common stock, issued Common stock, outstanding Common stock, $.001 par value, 75,000,000 shares authorized, 20,012,080 and 18,521,951 issued and outstanding at June 30, 2011 and December 31, 2010, respectively Contract service revenue Convertible Notes Payable, Noncurrent Convertible notes payable Convertible Notes Payable Cost of services Current Fiscal Year End Date Issuance of common stock in payment of debt Debt Disclosure [Text Block] CONVERTIBLE NOTES PAYABLE Deferred Compensation Liability, Classified, Noncurrent Deferred compensation Deferred compensation - current portion Deferred Compensation Plans Disclosure [Text Block] Deferred Compensation Plans Disclosure [Text Block] DEFERRED COMPENSATION Debt issuance cost, net of accumulated amortization of $47,860 and $29,289 Deferred revenue recognized but not to be included in current operations cash flows. Non-cash write off of deferred revenue Deferred Revenue, Current Deferred revenue Deferred Revenue, Noncurrent Deferred revenue Depreciation and amortization ACCOUNTING FOR STOCK-BASED COMPENSATION Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Accounts Receivable Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Expenses Accounts Payable Accounts Payable Intangible assets, net Disposal Group, Including Discontinued Operation, Other Current Assets Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Other Liabilities Capital lease payable Disposal Group, Including Discontinued Operation, Other Noncurrent Liabilities Payroll related liabilities Equipment and leasehold improvements, net SALE OF BIO-QUANT Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Year Focus Document Information [Line Items] Document Period End Date Document Type Basic and diluted loss per common share LOSS PER SHARE Payroll related liabilities Entities [Table] Entity Central Index Key Entity Common Stock, Shares Outstanding Entity [Domain] Entity Filer Category Entity Registrant Name Equity Component [Domain] Non-cash loss on sale of Bio-Quant subsidiary Non-cash loss on sale of Bio-Quant subsidiary Loss on disposal of fixed assets Loss on disposal of fixed assets Loss on sale of Bio-Quant subsidiary Loss on sale of Bio-Quant subsidiary General and administrative Gross Profit Gross profit Income Statement [Abstract] INCOME TAXES Increase (decrease) in accounts payable and accrued expenses Decrease (increase) in accounts receivable Decrease (increase) in accounts receivable Decrease (increase) in deferred compensation Increase (decrease) in deferred revenue Decrease in due from related party Decrease in due from related party Decrease in due to related party Increase (decrease) in payroll related liabilities Changes in operating assets and liabilities Increase (decrease) in accrued rental income and other assets Increase (decrease) in accrued rental income and other assets Decrease (increase) in other receivable Decrease (increase) in other receivable Increase (decrease) in prepaid expenses and other assets Increase (decrease) in prepaid expenses and other assets Release (deposit) of restricted cash Release (deposit) of restricted cash INTANGIBLE ASSETS Intangible assets, net of accumulated amortization Interest expense, net Cash paid for interest Legal Entity [Axis] Total liabilities Total liabilities Total liabilities and stockholders' equity Total liabilities and stockholders' equity Liabilities and Stockholders' Equity Total current liabilities Total current liabilities Current liabilities Long term liabilities License fee revenue Line of Credit Facilities [Text Block] LINES OF CREDIT Net cash provided by financing activities Net cash provided by financing activities Cash flows from financing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Cash flows from investing activities Net cash used in operating activities Net cash used in operating activities Cash flows from operating activities Net loss Net Loss Total other income (expense) Total other income (expense) Other income (expense) Notes Payable Disclosure [Text Block] NOTES PAYABLE Notes Payable [Member] Notes payable to former Bio-Quant shareholders Notes to Financial Statements [Abstract] Notes to Financial Statements [Abstract] Total costs and expenses Total costs and expenses Costs and expenses Loss from operations Loss from operations BASIS OF PRESENTATION Accrued rental income and other assets Non-cash interest, amortization of beneficial conversion feature and deferred financing costs Non-cash interest, amortization of beneficial conversion feature and deferred financing costs Other receivable Capital expenditures Capital expenditures Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Proceeds from issuance of convertible notes payable, net of debt issue costs Proceeds from Issuance of Common Stock Issuance of common stock, net of offering costs Proceeds from issuance of convertible notes payable Proceeds from (payments for) the sale of subsidiary stock. Proceeds from sale of Bio-Quant subsidiary Repayment of short-term borrowing Proceeds from sale of fixed assets Proceeds from exercise of warrants Fixed assets, net Reserve for related party note receivable RELATED PARTY TRANSACTIONS Rental income Repayment of convertible notes payable Repayment of convertible notes payable Repayment of capital lease obligations Repayment of capital lease obligations Research and development Restricted cash Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Deficit Total revenue Total revenue Scenario, Unspecified [Domain] SEGMENT INFORMATION Non-cash compensation expense Shares, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Short-term borrowing from banks Significant Agreements Disclosure [Text Block] LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS Statement, Equity Components [Axis] Statement [Line Items] Statement of Cash Flows [Abstract] Statement of Financial Position [Abstract] Statement of Stockholders' Equity [Abstract] Statement, Scenario [Axis] Statement [Table] Stockholder Rights Plan Disclosure STOCKHOLDER RIGHTS PLAN Total stockholders' equity Ending Balance Beginning Balance Total stockholders' equity Stockholders' equity: WARRANTS Number of shares issued during the period as a result of reissuance of treasury stock for Director stock awards. Issuance of compensatory stock to the board of directors (in shares) Issuance of common stock, net of offering costs (in shares) Issuance of stock and compensation expense for employees (in shares) Number of shares issued during the period as a result of the exercise of warrants. Issuance of common stock upon exercise of warrants (in shares) Value of reissuance of treasury stock for Director stock awards. Issuance of compensatory stock to the board of directors Stock Issued During Period, Value, New Issues Issuance of common stock, net of offering costs Issuance of stock and compensation expense for employees Value stock issued during the period as a result of the exercise of warrants. Issuance of common stock upon exercise of warrants Supplemental Information: Trading Symbol Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line Weighted average common shares outstanding used for basic and diluted loss per share